Strategy for randomised clinical trials in rare cancers

Say Beng Tan; Keith B.G. Dear; Paolo Bruzzi; David Machin

doi:10.1136/bmj.327.7405.47

Strategy for randomised clinical trials in rare cancers

Say Beng Tan^*, Keith B.G. Dear, Paolo Bruzzi, David Machin

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

65 Citations (Scopus)

Abstract

Proving that a new treatment is more effective than current treatment can be difficult for rare conditions. Data from small randomised trials could, however, be made more robust by taking other related research into account.

Original language	English
Pages (from-to)	47-49
Number of pages	3
Journal	The BMJ
Volume	327
Issue number	7405
DOIs	https://doi.org/10.1136/bmj.327.7405.47
Publication status	Published - 5 Jul 2003

Access to Document

10.1136/bmj.327.7405.47

Cite this

@article{e9a2c183730e4ceaaf126b6f3439c04a,

title = "Strategy for randomised clinical trials in rare cancers",

abstract = "Proving that a new treatment is more effective than current treatment can be difficult for rare conditions. Data from small randomised trials could, however, be made more robust by taking other related research into account.",

author = "Tan, {Say Beng} and Dear, {Keith B.G.} and Paolo Bruzzi and David Machin",

year = "2003",

month = jul,

day = "5",

doi = "10.1136/bmj.327.7405.47",

language = "English",

volume = "327",

pages = "47--49",

journal = "The BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

number = "7405",

}

TY - JOUR

T1 - Strategy for randomised clinical trials in rare cancers

AU - Tan, Say Beng

AU - Dear, Keith B.G.

AU - Bruzzi, Paolo

AU - Machin, David

PY - 2003/7/5

Y1 - 2003/7/5

N2 - Proving that a new treatment is more effective than current treatment can be difficult for rare conditions. Data from small randomised trials could, however, be made more robust by taking other related research into account.

AB - Proving that a new treatment is more effective than current treatment can be difficult for rare conditions. Data from small randomised trials could, however, be made more robust by taking other related research into account.

UR - http://www.scopus.com/inward/record.url?scp=0037707487&partnerID=8YFLogxK

U2 - 10.1136/bmj.327.7405.47

DO - 10.1136/bmj.327.7405.47

M3 - Review article

SN - 0959-8146

VL - 327

SP - 47

EP - 49

JO - The BMJ

JF - The BMJ

IS - 7405

ER -

Strategy for randomised clinical trials in rare cancers

Abstract

Access to Document

Other files and links

Fingerprint

Cite this